华西医学

华西医学

2017 年第 4 版 NCCN 卵巢癌临床实践指南解读

查看全文

卵巢恶性肿瘤是女性生殖器官常见的恶性肿瘤之一,发病率仅次于子宫颈癌和子宫体癌而列居第 3 位,但其死亡率居各类妇科肿瘤首位,对妇女生命健康造成严重威胁。近年来美国国立综合癌症网络(National Comprehensive Cancer Network)发布的 NCCN 卵巢癌临床实践指南已成为卵巢癌诊治的重要依据之一。为更好地将其应用于临床,该文对新版指南进行了简要解读。

Ovarian cancer is one of the common malignant tumors of female genital organs. In gynecological tumors, the incidence rate of ovarian cancer ranks the third after cervical cancer and uterine body cancer, but the death rate of ovarian cancer ranks the first, posing a serious threat to women’s life and health. In recent years, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for ovarian cancer has become an important basis for diagnosis and treatment of ovarian cancer. In this paper, we interpret the latest version (version 4. 2017) of NCCN clinical practice guidelines for ovarian cancer for its better clinical application.

关键词: 卵巢癌; NCCN 临床实践指南; 解读

Key words: Ovarian cancer; NCCN clinical practice guidelines; Interpretation

引用本文: 李克敏, 宋亮, 尹如铁. 2017 年第 4 版 NCCN 卵巢癌临床实践指南解读. 华西医学, 2018, 33(4): 398-402. doi: 10.7507/1002-0179.201712109 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 4.2017). (2017-11-09)[2018-02-02]. https://www.nccn.org/professionals/physician.
2. Pujade-Lauraine E, Ledermann JA, Selle FA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2017, 18(9): 1274-1284.
3. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol, 2015, 16(8): 928-936.
4. Duska LR, Java JJ, Cohn DE, et al. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236) Gynecol Oncol, 2015, 139(2): 221-227.
5. Kim JW, Mahner S, Wu LY, et al. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study. Int J Gynecol Cancer, 2018, 28(1): 2-10.
6. Committee on Practice Bulletins-Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice bulletin no 182: hereditary breast and ovarian cancer syndrome. Obstet Gynecol, 2017, 130(3): e110-e126.
7. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase Ⅲ GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer, 2012, 107(4): 588-591.
8. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003, 361(9375): 2099-2106.
9. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol, 2006, 24(29): 4699-4707.